Phase 2 Immunotherapy Clinical Trials
69 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 69 trials
Recruiting
Phase 2
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
Consolidation ImmunotherapyChemoradiotherapyLimited-stage Small Cell Lung Cancer (LS-SCLC)+1 more
Shanghai Chest Hospital28 enrolled1 locationNCT07091305
Recruiting
Phase 2
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Bladder CancerImmunotherapyLiquid Biopsy
Tianjin Medical University Second Hospital53 enrolled3 locationsNCT07475403
Recruiting
Phase 2
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Hepatocellular CarcinomaRadiotherapyImmunotherapy+3 more
Shandong Cancer Hospital and Institute54 enrolled1 locationNCT07062055
Recruiting
Phase 2
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
Head and Neck Squamous Cell CarcinomaTargeted TherapyImmunotherapy+1 more
West China Hospital98 enrolled1 locationNCT07040956
Recruiting
Phase 2
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Colorectal, CancerRadiotherapyTargeted Therapy+2 more
Shandong Cancer Hospital and Institute62 enrolled1 locationNCT06356584
Recruiting
Phase 2
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
ChemotherapyRectal CancerRadiotherapy+1 more
Tao Zhang25 enrolled1 locationNCT07239466
Recruiting
Phase 2
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
Breast CancerTriple Negative Breast Cancer(TNBC)Early Stage Breast Cancer+2 more
Sun Yat-sen University192 enrolled5 locationsNCT06768931
Recruiting
Phase 2
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
Acute Lymphoblastic LeukemiaImmunotherapyBlinatumomab+1 more
The First Affiliated Hospital of Soochow University26 enrolled1 locationNCT06985485
Recruiting
Phase 2
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
NSCLCImmunotherapyStereotactic Body Radiation Therapy (SBRT)
Fudan University27 enrolled1 locationNCT06738160
Recruiting
Phase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting
Phase 2
TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus
Immunotherapy-related Pruritus
University of California, San Diego28 enrolled1 locationNCT06748404
Recruiting
Phase 2
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
MRDNSCLC (Non-small Cell Lung Cancer)II-IIIB Stages+1 more
Guangdong Association of Clinical Trials115 enrolled2 locationsNCT07120698
Recruiting
Phase 2
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
Neoadjuvant Immunotherapy
Tianjin Medical University Second Hospital21 enrolled1 locationNCT05837806
Recruiting
Phase 2
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
Ovarian CancerImmunotherapyPembrolizumab
Obstetrics & Gynecology Hospital of Fudan University20 enrolled1 locationNCT07261683
Recruiting
Phase 2
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
ImmunotherapyAFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4+1 more
Hebei Medical University Fourth Hospital39 enrolled1 locationNCT07289997
Recruiting
Phase 1Phase 2
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Esophageal CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+22 more
VM Oncology, LLC242 enrolled15 locationsNCT03556228
Recruiting
Phase 2
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Biliary Tract Neoplasms Immunotherapy
Peking Union Medical College Hospital60 enrolled1 locationNCT06230471
Recruiting
Phase 1Phase 2
Personalized Neoantigen Peptide Vaccines for Solid Tumors
Solid TumorsAdvanced CancerRecurrent Cancer+2 more
Seqker Biosciences, Inc.10 enrolled2 locationsNCT07002203
Recruiting
Phase 1Phase 2
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
ChemotherapyGastroesophageal Junction AdenocarcinomaImmunotherapy+1 more
West China Hospital88 enrolled4 locationsNCT07072351
Recruiting
Phase 1Phase 2
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
ImmunotherapyColorectal Cancer MetastaticColorectal Cancer (CRC)+1 more
Anbogen Therapeutics, Inc.66 enrolled15 locationsNCT07244705